Literature DB >> 9187275

Carbamazepine inhibition of neuronal Na+ currents: quantitative distinction from phenytoin and possible therapeutic implications.

C C Kuo1, R S Chen, L Lu, R C Chen.   

Abstract

Carbamazepine and phenytoin, two of the most commonly prescribed antiepileptic drugs, have been proposed to share a similar mechanism of action by use-dependent inhibition of Na+ channels. The proposed similar mechanism of action, however, cannot explain the common clinical experiences that the two drugs are different; in some patients, one drug may be more effective than the other. This may occur even when optimal therapeutic concentrations are reached with both medications in plasma or the cerebrospinal fluid. In this study, we show that the action of the two drugs on Na+ channels are quantitatively very different. The affinity between inactivated Na+ channels and carbamazepine (apparent dissociation constant approximately 25 microM) is approximately 3 times lower than that of phenytoin, yet the binding rate constant of carbamazepine onto the inactivated Na+ channels is approximately 38,000 M(-1)/sec(-1), or approximately 5 times faster than that of phenytoin. It is speculated that carbamazepine may be more effective than phenytoin in treating seizures whose ictal depolarization shift is relatively short, whereas a better response to phenytoin may imply abnormal discharges characterized by more prolonged depolarization.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9187275     DOI: 10.1124/mol.51.6.1077

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  40 in total

1.  Flufenamic acid decreases neuronal excitability through modulation of voltage-gated sodium channel gating.

Authors:  Hau-Jie Yau; Gytis Baranauskas; Marco Martina
Journal:  J Physiol       Date:  2010-08-19       Impact factor: 5.182

2.  Precision Medicine: SCN8A Encephalopathy Treated with Sodium Channel Blockers.

Authors:  Rikke S Møller; Katrine M Johannesen
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

3.  Mutant bacterial sodium channels as models for local anesthetic block of eukaryotic proteins.

Authors:  Natalie E Smith; Ben Corry
Journal:  Channels (Austin)       Date:  2016-02-06       Impact factor: 2.581

4.  An inactivation stabilizer of the Na+ channel acts as an opportunistic pore blocker modulated by external Na+.

Authors:  Ya-Chin Yang; Chung-Chin Kuo
Journal:  J Gen Physiol       Date:  2005-04-11       Impact factor: 4.086

5.  Changing channels: mechanisms and responsiveness to antiepileptic drugs in chronic epilepsy.

Authors:  Graeme J Sills
Journal:  Epilepsy Curr       Date:  2004 May-Jun       Impact factor: 7.500

6.  Regulation of persistent Na current by interactions between beta subunits of voltage-gated Na channels.

Authors:  Teresa K Aman; Tina M Grieco-Calub; Chunling Chen; Raffaella Rusconi; Emily A Slat; Lori L Isom; Indira M Raman
Journal:  J Neurosci       Date:  2009-02-18       Impact factor: 6.167

7.  Sidedness of carbamazepine accessibility to voltage-gated sodium channels.

Authors:  Sooyeon Jo; Bruce P Bean
Journal:  Mol Pharmacol       Date:  2013-12-06       Impact factor: 4.436

8.  Scutellarin blocks sodium current in freshly isolated mouse hippocampal CA1 neurons.

Authors:  Guangqin Zhang; Suhua Qiu; Heming Wei
Journal:  Neurochem Res       Date:  2011-02-22       Impact factor: 3.996

9.  Properties of human brain sodium channel α-subunits expressed in HEK293 cells and their modulation by carbamazepine, phenytoin and lamotrigine.

Authors:  Xin Qiao; Guangchun Sun; Jeffrey J Clare; Taco R Werkman; Wytse J Wadman
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

10.  Modulation of sodium channel inactivation gating by a novel lactam: implications for seizure suppression in chronic limbic epilepsy.

Authors:  Paulianda J Jones; Ellen C Merrick; Timothy W Batts; Nicholas J Hargus; Yuesheng Wang; James P Stables; Edward H Bertram; Milton L Brown; Manoj K Patel
Journal:  J Pharmacol Exp Ther       Date:  2008-10-24       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.